Thomas Pilgrim (Bern, Switerland) details two-year results from the BIOSTEMI randomised trial, which were presented during a late-breaking trial session at the 2021 Cardiovascular Research Technologies meeting (CRT 21 Virtual, 13 February–24 April).
The trial compared safety and efficacy of two newer-generation drug-eluting stents in patients with acute myocardial infarction—Orsiro (Biotronik) an ultrathin, sirolimus-eluting stent with a biodegradable polymer to the Xience Xpedition (Abbott) durable polymer everolimus-eluting stent.
“In patients presenting with ST-segment elevation myocardial infarction (STEMI) biodegradable polymer sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with regard to target lesion failure at two-years,” Pilgrim tells Cardiovascular News.
The findings support the idea that even small differences in stent design may lead to important differences in clinical outcomes, Pilgrim said, adding that based upon these new data, biodegradable polymer sirolimus-eluting stents “may be the new benchmark drug-eluting stent”.
